Consolidation therapy for multiple myeloma
Consolidation therapy for multiple myeloma is given after a stem cell transplant. It’s a short course of chemotherapy that helps make the previous chemotherapy treatment and stem cell transplant work better. Consolidation therapy also helps to keep the multiple myeloma in remission for longer.
Consolidation therapy for people with multiple myeloma who have had a stem cell transplant is most often the VRD regimen. The VRD regimen uses bortezomib (Velcade), lenalidomide (Revlimid) and dexamethasone (Decadron, Dexasone).
Great progress has been made
Some cancers, such as thyroid and testicular, have survival rates of over 90%. Other cancers, such as pancreatic, brain and esophageal, continue to have very low survival rates.
